Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: A pilot study

Bone Marrow Transplantation

Volumn 28, Issue 8, 2001, Pages 759-763

  Chakrabarti, S ^a   Collingham, K E ^a   Holder, K ^a   Fegan, C D ^a   Osman, H ^a   Milligan, D W ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Oral ribavirin; Respiratory virus

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIVIRUS AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; MELPHALAN; METRONIDAZOLE; MYELOABLATIVE AGENT; RIBAVIRIN; STEROID;

ADULT; AEROSOL; ANEMIA; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DRUG TOXICITY; DRUG USE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MORBIDITY; MORTALITY; PARAINFLUENZA VIRUS; PARAMYXOVIRUS; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; ANEMIA; ANEMIA, APLASTIC; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NAUSEA; PARAINFLUENZA VIRUS 3, HUMAN; PILOT PROJECTS; PNEUMONIA, VIRAL; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; RIBAVIRIN; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0035176383     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703216     Document Type: Article

References (17)

1. Respiratory virus infections in bone marrow transplant recipients: The European perspective
2. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience
3. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients
4. Community respiratory virus infections in immunocompromised patients with cancer
5. Parainfluenza virus respiratory infection after bone marrow transplantation
6. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirinand intravenous immunoglobulin
7. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV
8. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation
9. Parainfluenza virus type 3 infections in haematopoetic stem cell transplant recipients: Response to ribavirin therapy
10. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy
11. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections
12. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
13. Respiratory virus infections in adult T cell depleted transplant recipients: Role of cellular immunity
14. The clinical pharmacology of ribavirin
15. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
16. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells
17. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4(+) T cell responses